St. Jude Medical Inc. (NYSE:STJ) said Thursday it paid $16 million to end a government investigation determining whether the company paid doctors who put its heart device in their patients.
stjudemedical
St. Jude and Zonare combine for new cardiac ultrasound system
Two months after it announced a development agreement with an ultrasound technology company, St. Jude Medical Inc. (NYSE:STJ) has launched a faster, more portable intracardiac ultrasound system designed for taking images inside the heart.
The company’s new ViewMate Z combines its intracardiac echocardiography catheter with Mountain View, Calif.-based Zonare Medical Systems Inc.’s "z.one" convertible ultrasound system.
St. Jude primes share price with better than expected sales performance
St. Jude Medical Inc. (NYSE:STJ) reported better than expected sales results for its fourth quarter.
The St. Paul, Minn.-based medical device maker reported revenues from the period ending Jan. 1 of $1.35 billion, including $25 million contribution from the November acquisition of AGA Medical Holdings Inc. The results represented an increase of approximately 12 percent over the same period in 2009 and outstripped the analyst consensus projection of $1.29 billion and the company’s own forecast of $1.30 billion.
ICD slowdown costs St. Jude as Morgan Stanley downgrades
For St. Jude Medical Inc. (NYSE:STJ), last year’s blessing may be this year’s curse.
The medical device maker, based in Little Canada, Minn., enjoyed a stellar 2010, mostly due to impressive growth in its pacemaker and implantable cardioverter defibrillator business.
Intelect reportedly finds a buyer from its new Boston digs
The neuromodulation medical device company Intelect Medical Inc. recently left its Cleveland headquarters for Boston. Now it may be in for a departure of another order — namely, an exit.
St. Jude pulls defibrillator leads
St. Jude Medical Inc. (NYSE:STJ) is removing certain defibrillator leads from the market over concerns that their electrical insulation could cause the devices to malfunction.
The St. Paul, Minn.-based medical device maker sent a letter to doctors yesterday saying that a newer version of leads, which have a different coating, already represent 97 percent of the market, The Wall Street Journal reported.
St. Jude making progress in neuromodulation market
St. Jude Medical Inc. (NYSE:STJ) reintroduced physicians at the North American Neuromodulation Society meeting in Las Vegas to its Penta surgical lead for neurostimulation therapy.
Since last year’s society meeting, during which St. Jude announced Food & Drug Administration clearance to sell the device in the United States, St. Jude has received CE Mark approval to sell the device in Europe and reimbursement approval from the Australian Therapeutic Goods Administration.
St. Jude, Justice Dept. near settlement in kickbacks case
St. Jude Medical Inc. (STJ) and the U.S. Justice Dept. remain in talks over the company’s alleged kickbacks to doctors, but a settlement may be within sight.
The case stems from a 2006 whistleblower lawsuit filed by former employee Charles Donigian that accused the company of offering kickbacks to doctors, hospitals and other healthcare providers in the form of travel and tickets to sporting events to influence them to use certain St. Jude products.
Medical device giants begin to reap benefits from early investment strategies
Clinical trials roundup: Medtronic, St. Jude, Covidien tout studies
A trio of big-name medical device makers are touting the results of clinical trials for several products designed to monitor or treat atrial fibrillation, stroke, thoracic and abdominal aortic aneurysms and unexplained fainting.
St. Jude closes AGA Medical buyout
St. Jude Medical Inc. (NYSE:STJ) closed its $1.03 billion acquisition of rival cardiovascular device maker AGA Medical Holdings Inc. (NSDQ:AGAM) today.
The St. Paul, Minn.-based medical device developer said the acquisition gives it access to four new surgical markets, including the treatment of structural defects in the heart.